Mayo Clinic has formed a collaboration with precision medicine platform vendor 2bPrecise to develop genomics-based care protocols.
Pittsburgh-based 2bPrecise, a subsidiary of health IT vendor Allscripts, said it was interested in partnering with Mayo Clinic because of its expertise and experience in the area of clinical genomics, specifically its research in familial hypercholesterolemia (FH). Mayo also has expressed a desire to share its care algorithms more broadly with the medical community.
Taking advantage of Mayo Clinic’s expertise and electronic phenotyping algorithms, 2bPrecise said it would incorporate these new clinical protocols, and apply them in research to measure outcomes in patients with cardiovascular genetic disease.
“Mayo Clinic has a very robust genomics research discipline,” said Assaf Halevy, founder and CEO of 2bPrecise, in a prepared statement. “The wealth of both genetic research and clinical data within the clinic is staggering. This is why we are so excited to collaborate with premier organizations like Mayo Clinic to advance genomic science and help make it clinically actionable.” (Halevy joined Allscripts in 2013 as senior vice president of products and business development when the company acquired dbMotion.
The 2bPrecise platform is designed to harmonize clinical and genomic information to extract patient-specific insights and present them in an actionable way to the clinician, within their current EHR workflow.
The two organizations will begin their collaboration by bringing Mayo Clinic's algorithm for FH into the 2bPrecise platform to derive insights from combined clinical and genomic research data.
